The North American journal Medicine, specialized in research articles in medical scientific disciplines and subspecialties, has recently published the clinical case of Repigment12.

In the article, signed by Dr Matteo Bordignon (dermatologist specialized in vitiligo), Jordi Segura (R&D Director of Bella Aurora), Sergi Hernández (Fundamental Research Manager of Bella Aurora), and Marta Bajona (Medical Advisor of Bella Aurora) among others, the results of the studies conducted on the use of MIA inhibitors for the treatment of hypopigmentation are presented.

The scientific journal Medicine, through an expert committee, certifies the scientific, technical, and ethical validity of the studies conducted and ensures compliance with high-quality standards. In addition, the journal endorses the clinical case presented by Bella Aurora laboratories and Dr Matteo Bordignon, demonstrating the effectiveness of Repigment12.

Repigment12 is the result of more than 4 years of collaboration between Bella Aurora laboratories and Dr Matteo Bordignon, an Italian dermatologist specializing in vitiligo. In May 2021, it was launched as the first cosmetic treatment for white spots by Bella Aurora.

To read the full scientific paper, click here.